Access to Medicine
Social Impact in Life Sciences: broadening Access to Medicine for patients
The pharmaceutical industry is transitioning toward a more sustainable and inclusive model, where health equity and social impact are becoming a growing component of value creation. Significant industry progress on ESG has been made already and is accelerating, with pharmaceutical companies focusing efforts on expanding access to their products and solutions: a pharma-specific topic that requires to rethink the existing access paradigm.
A momentum for the life sciences industry to act
In the health ecosystem, life sciences companies are recognized by all stakeholders to play a critical role in addressing health inequities, through their direct and indirect impacts on individual and community health.
Underserved population
Some populations still have inadequate access to medical care and/or are disproportionately affected by health issues, including populations in low- & middle-income countries (LMICs) and underserved populations in high-income countries (HICs) (e.g., low social-economic status groups; racial & ethnic minorities; individuals living in rural areas; individuals with limited autonomy such as the elderly).
Urban regions tend to have a greater number of doctors, reflecting the concentration of specialized services such as surgery care.
Women of African descent, although disproportionately affected by TNBC – the most aggressive breast cancer subtype – struggle to access adequate care for this disease in both LMICs and HICs (e.g., when the mode of administration is not adapted to low-resources settings).
Under-addressed diseases
Many diseases still lack adequate attention and/or appropriate treatment solutions (e.g., when the route of administration / mode of administration is not adapted to low-resources settings, the treatment cannot effectively reach patients in certain LMICs), requiring accelerated R&D efforts by pharma companies.
Insulin drugs must be kept cool from manufacturing until the product is used by the patient; Yet in LMICs, infrastructure for refrigerated storage and supply chain refrigeration can be lacking, resulting in restricted access to insulin for people with diabetes.
We support life sciences companies as they embark on their journey towards a more inclusive model
> We leverage our expertise in life sciences and access planning to support both biotech and global pharmaceutical companies to broaden access to their products.
For each type of support, we leverage our proprietary tools and frameworks – the Deloitte “accelerators” (e.g., Access Barriers Framework).
> We also support organizations in their transformation journey towards improved Access to Medicine, by developing necessary capabilities.
Why Deloitte?
- Our leading expertise at the intersection of Life Sciences, Access Planning and Sustainability
- Deloitte accelerators : our comprehensive set of access to medicine proprietary tools and frameworks
- A unique positioning within the global health ecosystem, with long-standing relationships with leading organizations driving access
Nos points de vue
Opens in new window